- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
7
Companies with a Value score of at least 3, ordered by Value score
7 companies
Bavarian Nordic
Market Cap: DKK 13.8b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 180.70
7D
0.8%
1Y
-24.4%
H. Lundbeck
Market Cap: DKK 40.1b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 41.68
7D
0.4%
1Y
17.1%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 299.50
7D
1.8%
1Y
-8.1%
H. Lundbeck
Market Cap: DKK 40.1b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 35.45
7D
-0.1%
1Y
18.8%
Gubra
Market Cap: DKK 6.1b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 376.40
7D
2.2%
1Y
9.9%
Genmab
Market Cap: DKK 121.6b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 2,037.00
7D
7.7%
1Y
41.7%
Strategic Partners
Market Cap: DKK 29.2m
Does not have significant operations.
STRAP
DKK 700.00
7D
-6.0%
1Y
-31.7%